Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma

PURPOSE: The phase III CELESTIAL study demonstrated improved overall survival (OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with previously treated, advanced hepatocellular carcinoma (HCC). We analyzed outcomes by baseline alpha-fetoprotein (AFP) and on-treatm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Kelley, Robin Kate, Meyer, Tim, Rimassa, Lorenza, Merle, Philippe, Park, Joong-Won, Yau, Thomas, Chan, Stephen L., Blanc, Jean-Frederic, Tam, Vincent C., Tran, Albert, Dadduzio, Vincenzo, Markby, David W., Kaldate, Rajesh, Cheng, Ann-Lii, El-Khoueiry, Anthony B., Abou-Alfa, Ghassan K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7779341/
https://ncbi.nlm.nih.gov/pubmed/32636319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3884
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados